The Central Drugs Standard Control Organisation (CDSCO) has raised concerns over the quality of 51 drug samples, including widely used medications such as paracetamol, pantoprazole, and various antibiotics. This quality failure highlights potential risks for patients relying on these medications.
Details of the Report
In a report released on June 20, CDSCO, India’s drugs regulatory body, indicated that 22 of these substandard drugs were manufactured in Himachal Pradesh. Other samples were collected from Jaipur, Hyderabad, Waghodia, Vadodara, Andhra Pradesh, and Indore. The drug regulator has issued notices to the pharmaceutical companies responsible and has initiated a recall of the failed samples from the market.
Full List of Drugs That Failed Quality Tests
- Cyra Tablets – Rabeprazole Sodium Tablets IP
- Rabedin Tablets – Rabeprazole Sodium Gastro-Resistant Tablets IP
- Moxtas Distab 250 Tablets – Amoxycillin Trihydrate Dispersible Tablets IP
- Tolcenta-P Tablets – Tolperisone Hydrochloride and Paracetamol Tablets
- Nagris Pakeezah Art Henna
- Oxifer-XT Tablets – Ferrous Ascorbate Elemental Iron, Folic Acid, and Zinc Sulphate Tablets
- Levolets-M Kid Syrup – Montelukast Sodium & Levocetirizine Dihydrochloride Syrup
- Meazon Plus Injection – Mecobalamine, Folic Acid & Niacinamide Injection 1 ml
- Xeronac-SP Tablets – Aceclofenac, Paracetamol and Serratiopeptidase Tablets
- Pedxim-200 Tablets – Cefpodoxime Proxetil Tablets 200 mg
- DofloxOZT Tablets – Ofloxacin & Ornidazole Tablets
- Disinfectants – Surgical Spirit BP
- Sif Alben Suspension – Albendazole Oral Suspension 2.5% w/v (Vet)
- Terbutaline Sulfate, Bromhexine Hydrochloride with Guaiphenesin Syrup
- Metoprolol Succinate Extended Release Tablets IP
- Cuftin Cough Linctus
- Cefuroxime Axetil Tablets IP
- Levosalbutamol Sulphate, Ambroxol HCL, Guaiphenesin Syrup
- Acetylsalicylic Acid Tablets 75 mg
- Lactulose Solution U.S.P.
- Terbutaline Sulphate, Bromhexine Hydrochloride, Guaiphenesin and Menthol Syrup
- Prednisolone Tablets IP 10 mg
- Mecobalamin, Alpha Lipoic Acid, Pyridoxine Hydrochloride and Folic Acid Soft Gelatin Capsules
- Telmisartan And Amlodipine Tablets IP
- Cefoperazone & Sulbactam for Injection
- Cefotaxime Injection IP 500 mg
- Dexamethasone Sodium Phosphate Injection I.P
- Amoxycillin & Potassium Clavulanate Injection IP 1.2 gm
- Telmisartan and Metoprolol Succinate (Extended Release) Tablets
- Pantoprazole Tablets IP
- Ambroxol HCl, Levosalbutamol and Guaiphenesin Syrup
- Dexamethasone Sodium Phosphate Injection I.P. (8mg/2ml)
- Dexamethasone Sodium Phosphate Injection IP
- Paracetamol 500 mg Tablets
- Ofloxacin Ornidazole Tablets IP
- Vildagliptin and Metformin Hydrochloride Tablets IP 50mg/1000mg
- Amoxycillin and Potassium Clavulanate Tablets I.P.
- Clonazepam Tablets I.P. 0.5 mg
- Metronidazole Extended Release Tablets USP 600 MG
- Diclofenac Sodium and Paracetamol Tablets IP
- Atropine Sulphate Injection IP
- Montelukast Sodium and Levocetirizine Hydrochloride Tablets
- Fluconazole Tablets IP (150 mg)
- Ceftriaxone Injection IP
- Ramipril and Hydrochlorothiazide Tablets IP
- Glipizide and Metformin Tablets IP
- Ceftriaxone for Injection I.P. 1 gm
- Gentamicin Sulphate Injection I.P. 2 ml
- Calcium 500 mg with Vitamin D3 250 IU Tablets IP
- Cefixime and Ofloxacin Tablets
- Ceftriaxone Injection IP
Implications and Actions
The failed quality tests have significant implications for public health, given the wide usage of these medications. The CDSCO’s action to recall the substandard drugs and issue notices to the manufacturers is a crucial step towards ensuring drug safety and efficacy in the market.
Conclusion
The recent quality tests revealing 51 failed drug samples, including commonly used medications, highlight the ongoing challenges in drug manufacturing and regulation. The CDSCO’s proactive measures aim to safeguard public health and maintain trust in the pharmaceutical industry.
